The Wistar Institute

Wellesley Pharmaceuticals, LLC

Innate Biologics LLC

Frank J Rauscher, Iii

David A Dill

Meenhard Herlyn

Ulrich Rodeck

Jennifer Morris

David E Jensen

Peter Mondics

Provided herein are methods and compositions comprising a set of paired peptides comprising a first bacterial effector polypeptide or fragment thereof linked to a second bacterial effector polypeptide or fragment thereof. The paired peptides can be linked to a protein transduction domain. The compositions can be formulated as pharmaceuticals. The compositions are useful for the treatment of inflammatory disorders.

Methods and compositions for use of recombinant bacterial effector proteins as anti-inflammatory agents

Methods and compositions for reducing frequency of urination are disclosed. The methods comprise administering to a subject having a condition that resulting in undesired frequency of urination an effective amount of a pharmaceutical composition comprising one or more prostaglandin pathway inhibitors. The pharmaceutical compositions comprise one or more prostaglandin pathway inhibitors and a pharmaceutically acceptable carrier.

Pharmaceutical formulation for reducing frequency of urination and method of use thereof

Nucleic acid and amino acid sequences of a BRCA1 associated protein, BAP-1, are provided. These sequences, the protein, and anti-BAP-1 antibodies are useful in therapeutics and diagnostics for cancers associated with loss of the 3p21 chromosomal region and/or inappropriate BAP-1 levels.

BRCA1 associated polynucleotide (BAP-1) and uses therefor

The present invention provides three unique monoclonal antibodies directed against a portion of the Wilms' tumor antigen, and methods of use therefor in detecting, monitoring and diagnosing malignancies characterized by over-expression or inappropriate expression of the WT 1 protein.

WT1 monoclonal antibodies and methods of use therefor

Three unique monoclonal antibodies, each having an epitope located in amino acids 1-181 of the WT1 tumor protein, and the hybridomas which secrete them have been constructed. These monoclonal antibodies are useful in the detection, monitoring, and diagnosis of malignancies characterized by inappropriate expression of the WT1 protein.

Growing community of inventors

Wayne, PA, United States of America

Frank J Rauscher, Iii